MYH14 and ocular melanoma: Independent of clinical efficacy, OM, Mava, Dani, and Afi all modulate crossbridge cycling kinetics: a greater understanding of the impact of these small molecules on myosin structure and dynamics could pave the way for the development of more efficacious and targeted compounds.